Recent News

• 05.08.2025 - Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
• 03.27.2025 - Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
• 03.13.2025 - Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
• 03.06.2025 - Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit
• 02.21.2025 - Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance
• 01.30.2025 - Co-Diagnostics, Inc. to Exhibit at BioUtah's 2025 Life Sciences Day on the Hill
• 01.07.2025 - Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025
• 12.16.2024 - Co-Dx and CoSara inaugurate oligo synthesis facility in Ranoli, India
• 12.10.2024 - Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
• 11.27.2024 - The History of Tuberculosis Diagnostics

Recent Filings

• 04.28.2025 - EX-99.1 EX-99.1
• 04.28.2025 - 8-K Current report
• 04.14.2025 - DEF 14A Other definitive proxy statements
• 03.27.2025 - 8-K Current report
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - EX-99.1 EX-99.1
• 02.21.2025 - EX-99.1 EX-99.1
• 02.21.2025 - 8-K Current report
• 01.10.2025 - 8-K Current report
• 11.25.2024 - 4 Statement of changes in beneficial ownership of securities